Evotec SE and Indivumed GmbH entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer. The goal of the precision medicine collaboration is to deliver highly effective treatments for NSCLC patients.
Health Canada has approved Keytruda in combination with Inlyta for first-line treatment of patients with advanced renal cell carcinoma.
Responders who worked at the World Trade Center site after the attacks on Sept.11, 2001, have an increased overall cancer incidence, compared to the general population, particularly in thyroid cancer, prostate cancer, and, for the first time ever reported, leukemia, according to a Mount Sinai study published in JNCI Cancer Spectrum Jan. 14.
FDA has accepted a supplemental New Drug Application for Rubraca (rucaparib) and granted priority review status to the application with a Prescription Drug User Fee Act date of May 15.
FDA has accepted supplemental Biologics License Application for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.
Concerto HealthAI, a health IT company that develops AI technology for precision oncology, has:
Roche and Illumina have entered into a 15-year non-exclusive partnership with to broaden the adoption of distributable next-generation sequencing based testing in oncology.
Qiagen and Amgen are collaborating to develop tissue-based companion diagnostics for Amgen's investigational cancer treatment AMG 510 to identify patients with cancers that have the KRAS G12C mutation.
FDA approved Keytruda (pembrolizumab) Jan. 8 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
FDA approved Ayvakit (avapritinib) Jan. 9 for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
